Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions - PubMed (original) (raw)
Clinical Trial
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
Rory Collins et al. Lancet. 2004.
Abstract
Background: Lower blood cholesterol concentrations have consistently been found to be strongly associated with lower risks of coronary disease but not with lower risks of stroke. Despite this observation, previous randomised trials had indicated that cholesterol-lowering statin therapy reduces the risk of stroke, but large-scale prospective confirmation has been needed.
Methods: 3280 adults with cerebrovascular disease, and an additional 17256 with other occlusive arterial disease or diabetes, were randomly allocated 40 mg simvastatin daily or matching placebo. Subgroup analyses were prespecified of first "major vascular event" (ie, non-fatal myocardial infarction or coronary death, stroke of any type, or any revascularisation procedure) in prior disease subcategories. Subsidiary outcomes included any stroke, and stroke sub-type. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, "intention-to-treat"), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period.
Findings: Overall, there was a highly significant 25% (95% CI 15-34) proportional reduction in the first event rate for stroke (444 [4.3%] simvastatin vs 585 [5.7%] placebo; p<0.0001), reflecting a definite 28% (19-37) reduction in presumed ischaemic strokes (p<0.0001) and no apparent difference in strokes attributed to haemorrhage (51 [0.5%] vs 53 [0.5%]; rate ratio 0.95 [0.65-1.40]; p=0.8). In addition, simvastatin reduced the numbers having transient cerebral ischaemic attacks alone (2.0% vs 2.4%; p=0.02) or requiring carotid endarterectomy or angioplasty (0.4% vs 0.8%; p=0.0003). The reduction in stroke was not significant during the first year, but was already significant (p=0.0004) by the end of the second year. Among patients with pre-existing cerebrovascular disease there was no apparent reduction in the stroke rate, but there was a highly significant 20% (8-29) reduction in the rate of any major vascular event (406 [24.7%] vs 488 [29.8%]; p=0.001). The proportional reductions in stroke were about one-quarter in each of the other subcategories of participant studied, including: those with coronary disease or diabetes; those aged under or over 70 years at entry; and those presenting with different levels of blood pressure or lipids (even when the pretreatment LDL cholesterol was below 3.0 mmol/L [116 mg/dL]).
Interpretation: Much larger numbers of people in the present study suffered a stroke than in any previous cholesterol-lowering trial. The results demonstrate that statin therapy rapidly reduces the incidence not only of coronary events but also of ischaemic strokes, with no apparent effect on cerebral haemorrhage, even among individuals who do not have high cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rate of ischaemic strokes by about one-quarter and so, after making allowance for non-compliance in the trial, actual use of this regimen would probably reduce the stroke rate by about a third. HPS also provides definitive evidence that statin therapy is beneficial for people with pre-existing cerebrovascular disease, even if they do not already have manifest coronary disease.
Comment in
- New analyses of Heart Protection Study.
Lemiengre M, van Driel M, Chevalier P, De Meyere M, Christiaens T. Lemiengre M, et al. Lancet. 2004 May 29;363(9423):1827-8; author reply 1828. doi: 10.1016/S0140-6736(04)16316-2. Lancet. 2004. PMID: 15172789 No abstract available. - Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk of, vascular disease.
Ireland S. Ireland S. Evid Based Nurs. 2004 Jul;7(3):82. doi: 10.1136/ebn.7.3.82. Evid Based Nurs. 2004. PMID: 15252910 No abstract available. - Cholesterol lowering with simvastatin reduced stroke in patients with, or at risk for, vascular disease.
Johnston SC. Johnston SC. ACP J Club. 2004 Sep-Oct;141(2):32. ACP J Club. 2004. PMID: 15341452 No abstract available.
Similar articles
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. Collins R, et al. Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7. Lancet. 2003. PMID: 12814710 Clinical Trial. - MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group. Heart Protection Study Collaborative Group. Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. Lancet. 2002. PMID: 12114036 Clinical Trial. - Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Collins R, et al. Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Lancet. 2016. PMID: 27616593 Review. - The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
Heart Protection Study Collaborative Group. Heart Protection Study Collaborative Group. BMC Med. 2005 Mar 16;3:6. doi: 10.1186/1741-7015-3-6. BMC Med. 2005. PMID: 15771782 Free PMC article. Clinical Trial. - Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T. Thomopoulos C, et al. Clin Cardiol. 2015 Dec;38(12):763-9. doi: 10.1002/clc.22441. Epub 2015 Aug 18. Clin Cardiol. 2015. PMID: 26282344 Free PMC article. Review.
Cited by
- Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review.
Siniscalchi C, Imbalzano E, Meschi T, Ticinesi A, Prati B, Basaglia M, Camporese G, Perrella A, Viorica A, Eletto E, Russo V, Simioni P. Siniscalchi C, et al. Medicina (Kaunas). 2024 Jul 30;60(8):1240. doi: 10.3390/medicina60081240. Medicina (Kaunas). 2024. PMID: 39202521 Free PMC article. Review. - Brazilian Angiology and Vascular Surgery Society Guidelines for the treatment of extracranial cerebrovascular disease.
Ristow AVB, Massière B, Meirelles GV, Casella IB, Morales MM, Moreira RCR, Procópio RJ, Oliveira TF, de Araujo WJB, Joviliano EE, de Oliveira JCP. Ristow AVB, et al. J Vasc Bras. 2024 May 31;23:e20230094. doi: 10.1590/1677-5449.202300942. eCollection 2024. J Vasc Bras. 2024. PMID: 39099701 Free PMC article. - Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease.
Yang C, Wu YJ, Qian J, Li JJ. Yang C, et al. Rev Cardiovasc Med. 2023 Dec 29;24(12):373. doi: 10.31083/j.rcm2412373. eCollection 2023 Dec. Rev Cardiovasc Med. 2023. PMID: 39077097 Free PMC article. Review. - Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.
Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, Yeh RW, Kazi DS, Wadhera RK, Manrai AK. Diao JA, et al. JAMA. 2024 Sep 24;332(12):989-1000. doi: 10.1001/jama.2024.12537. JAMA. 2024. PMID: 39073797 - Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine.
Fusco L, Palamà Z, Scarà A, Borrelli A, Robles AG, De Masi De Luca G, Romano S, Sciarra L. Fusco L, et al. World J Cardiol. 2024 May 26;16(5):231-239. doi: 10.4330/wjc.v16.i5.231. World J Cardiol. 2024. PMID: 38817646 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical